European and U.S. Distributors in Place to Address $2B Market Opportunity MINNEAPOLIS, Aug. 31 /PRNewswire-FirstCall/ -- vasamed (OTC:OPTL) (BULLETIN BOARD: OPTL) , a leader in non-invasive, hemodynamic assessment technology, announced today that it has made initial customer shipments worldwide for its new AcQtrac(TM) Impedance Cardiography (ICG) Noninvasive Hemodynamic Assessment System. AcQtrac ICG is the newest generation of noninvasive solutions that assess cardiovascular functioning and provide physicians with rapid, reliable results. "AcQtrac ICG is a non-invasive cardiovascular diagnostic system that provides the hemodynamic information required to better assess and direct the treatment of advanced heart failure, hypertension and other cardiovascular diseases. The AcQtrac ICG is unique in its class since it provides a waveform 'image' of the heart that serves as a diagnostic aid and helpful tool in guiding drug therapy management," said Paulita LaPlante, President vasamed. "Cardiovascular disease is the nation's number one cause of death. Two out of three people with diabetes die of cardiovascular disease. As a woman, I am particularly focused on the tragedy that more women die of cardiovascular disease annually than they do from breast cancer. In fact more women than men in the U.S. die of heart disease and stroke. Research shows that it is more difficult to diagnose cardiovascular disease in women and we at vasamed want to be part of the medical strategies and solutions that improve outcomes for women as well as all patients." AcQtrac ICG System has generated great interest in Heart Failure Clinics, Private Office Cardiology, Critical Care Monitoring, Emergency Departments and Pediatric Cardiology. AcQtrac ICG is a welcome addition to many practices because non-invasive monitors are safer, more efficient and cost-effective to use than invasive counterparts. About vasamed. vasamed designs, licenses, manufactures and distributes products that can be used by your doctor -- right in the office -- to determine if heart and blood vessels are healthy. vasamed's products and technology include SensiLase(TM) Microvascular Assessment System to monitor small blood vessel health, AcQtrac(TM) Impedance Cardiography (ICG) to monitor heart function and Tissue Carbon Dioxide Technologies to monitor tissue wellness. For more information about vasamed technology and services and new products, please call (800) 695.2737 or see the company's web site at http://www.vasamed.com/ . DATASOURCE: vasamed CONTACT: Wes Peterson, CFO of vasamed, +1-952-944-5857 ext. 542 Web site: http://www.vasamed.com/

Copyright